Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
225Ac-LNC1011
- Development stage
- Phase 2
- Lead developer
- Yantai Lannacheng Biotechnology
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
225Ac-LNC1011 (also known as Dan-PSMA) is a novel radiopharmaceutical designed for targeted alpha therapy (TAT) in the treatment of prostate cancer. It consists of a prostate-specific membrane antigen (PSMA)-binding ligand conjugated to a dansylphenylalanine moiety and a DOTA chelator, radiolabeled with the alpha-emitting isotope Actinium-225 (225Ac). The addition of the dansylated amino acid is intended to optimize the drug's pharmacokinetic profile by increasing albumin binding, which leads to enhanced tumor uptake and prolonged retention within PSMA-positive lesions compared to earlier generation radioligands like PSMA-617. By delivering high-energy alpha particles directly to the tumor site, 225Ac-LNC1011 induces lethal double-strand DNA breaks in cancer cells while minimizing radiation exposure to surrounding healthy tissues. The drug is primarily being developed for metastatic castration-resistant prostate cancer (mCRPC).
- Other names
- Dan-PSMA[225Ac]-LNC1011注射液225Ac-labeled PSMA-targeted radioligand
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on 225Ac-LNC1011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 225Ac-LNC1011.